Utility of Daratumumab as Bridging Therapy in De Novo T-Cell Acute Lymphoblastic Lymphoma

Pediatr Blood Cancer. 2025 Jan 6:e31526. doi: 10.1002/pbc.31526. Online ahead of print.
No abstract available

Publication types

  • Letter